Spleis Helen, Sandmeier Matthias, Claus Victor, Bernkop-Schnürch Andreas
Department of Pharmaceutical Technology, Institute of Pharmacy, University of Innsbruck, Innrain 80/82, Innsbruck 6020, Austria; Thiomatrix Forschungs und Beratungs GmbH, Trientlgasse 65, Innsbruck 6020, Austria.
Department of Pharmaceutical Technology, Institute of Pharmacy, University of Innsbruck, Innrain 80/82, Innsbruck 6020, Austria.
Adv Colloid Interface Sci. 2023 Mar;313:102848. doi: 10.1016/j.cis.2023.102848. Epub 2023 Feb 3.
As nanocarriers (NCs) can improve the solubility of drugs, prevent their degradation by gastrointestinal (GI) enzymes and promote their transport across the mucus gel layer and absorption membrane, the oral bioavailability of these drugs can be substantially enhanced. All these properties of NCs including self-emulsifying drug delivery systems (SEDDS), solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), liposomes, polymeric nanoparticles, inorganic nanoparticles and polymeric micelles depend mainly on their surface chemistry. In particular, interaction with food, digestive enzymes, bile salts and electrolytes, diffusion behaviour across the mucus gel layer and fate on the absorption membrane are determined by their surface. Bioinert surfaces limiting interactions with gastrointestinal fluid and content as well as with mucus, adhesive surfaces providing an intimate contact with the GI mucosa and absorption enhancing surfaces can be designed. Furthermore, charge converting surfaces shifting their zeta potential from negative to positive directly at the absorption membrane and surfaces providing a targeted drug release are advantageous. In addition to these passive surfaces, even active surfaces cleaving mucus glycoproteins on their way through the mucus gel layer can be created. Within this review, we provide an overview on these different surfaces and discuss their impact on the performance of NCs in the GI tract.
由于纳米载体(NCs)可以提高药物的溶解度,防止其被胃肠道(GI)酶降解,并促进其穿过黏液凝胶层和吸收膜的转运,这些药物的口服生物利用度可以得到显著提高。NCs的所有这些特性,包括自乳化药物递送系统(SEDDS)、固体脂质纳米粒(SLNs)、纳米结构脂质载体(NLCs)、脂质体、聚合物纳米粒、无机纳米粒和聚合物胶束,主要取决于它们的表面化学性质。特别是,与食物、消化酶、胆汁盐和电解质的相互作用、穿过黏液凝胶层的扩散行为以及在吸收膜上的命运都由其表面决定。可以设计出限制与胃肠液和内容物以及与黏液相互作用的生物惰性表面、与胃肠道黏膜紧密接触的黏附性表面以及增强吸收的表面。此外,能在吸收膜处直接将其zeta电位从负变为正的电荷转换表面以及能实现靶向药物释放的表面也具有优势。除了这些被动表面,甚至可以制造出在穿过黏液凝胶层的过程中裂解黏液糖蛋白的活性表面。在这篇综述中,我们对这些不同的表面进行了概述,并讨论了它们对NCs在胃肠道中性能的影响。